tetano
Editor, Senior Moderator
J Clin Med
. 2021 Oct 28;10(21):5048.
doi: 10.3390/jcm10215048.
Liver Injury in Patients with Coronavirus Disease 2019 (COVID-19)-A Narrative Review
Liliana Łykowska-Szuber[SUP] 1 [/SUP], Karolina Wołodźko[SUP] 1 [/SUP], Anna Maria Rychter[SUP] 1 [/SUP], Aleksandra Szymczak-Tomczak[SUP] 1 [/SUP], Iwona Krela-Kaźmierczak[SUP] 1 [/SUP], Agnieszka Dobrowolska[SUP] 1 [/SUP]
Affiliations
Abstract
While respiratory symptoms are prevalent in SARS-CoV-2 infected patients, growing evidence indicates that COVID-19 affects a wide variety of organs. Coronaviruses affect not only the respiratory system, but also the circulatory, nervous and digestive systems. The most common comorbidities in COVID-19 patients are hypertension, followed by diabetes, cardiovascular, and respiratory disease. Most conditions predisposing to SARS-CoV-2 infection are closely related to the metabolic syndrome. Obesity and chronic diseases, including liver disease, are associated with the induction of pro-inflammatory conditions and a reduction in immune response disorders, leading to the suspicion that these conditions may increase the susceptibility to SARS-CoV2 infection and the risk of complications. The definition of liver damage caused by COVID-19 has not yet been established. COVID-19 may contribute to both primary and secondary liver injury in people with pre-existing chronic disease and impaired liver reserves, leading to exacerbation of underlying disease, liver decompensation, or acute chronic liver failure. Therefore, many researchers have interpreted it as clinical or laboratory abnormalities in the course of the disease and treatment in patients with or without pre-existing liver disease. The research results available so far indicate that patients with liver disease require special attention in the event of COVID-19 infection.
Keywords: COVID-19; clinical manifestations; liver disease.
. 2021 Oct 28;10(21):5048.
doi: 10.3390/jcm10215048.
Liver Injury in Patients with Coronavirus Disease 2019 (COVID-19)-A Narrative Review
Liliana Łykowska-Szuber[SUP] 1 [/SUP], Karolina Wołodźko[SUP] 1 [/SUP], Anna Maria Rychter[SUP] 1 [/SUP], Aleksandra Szymczak-Tomczak[SUP] 1 [/SUP], Iwona Krela-Kaźmierczak[SUP] 1 [/SUP], Agnieszka Dobrowolska[SUP] 1 [/SUP]
Affiliations
- PMID: 34768568
- DOI: 10.3390/jcm10215048
Abstract
While respiratory symptoms are prevalent in SARS-CoV-2 infected patients, growing evidence indicates that COVID-19 affects a wide variety of organs. Coronaviruses affect not only the respiratory system, but also the circulatory, nervous and digestive systems. The most common comorbidities in COVID-19 patients are hypertension, followed by diabetes, cardiovascular, and respiratory disease. Most conditions predisposing to SARS-CoV-2 infection are closely related to the metabolic syndrome. Obesity and chronic diseases, including liver disease, are associated with the induction of pro-inflammatory conditions and a reduction in immune response disorders, leading to the suspicion that these conditions may increase the susceptibility to SARS-CoV2 infection and the risk of complications. The definition of liver damage caused by COVID-19 has not yet been established. COVID-19 may contribute to both primary and secondary liver injury in people with pre-existing chronic disease and impaired liver reserves, leading to exacerbation of underlying disease, liver decompensation, or acute chronic liver failure. Therefore, many researchers have interpreted it as clinical or laboratory abnormalities in the course of the disease and treatment in patients with or without pre-existing liver disease. The research results available so far indicate that patients with liver disease require special attention in the event of COVID-19 infection.
Keywords: COVID-19; clinical manifestations; liver disease.